Round Rock Advisors
GLUE icon

Round Rock Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Round Rock Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-37,229
Closed -$901K – 318
2026
Q2 		$901K Hold
37,229
– – 0.12% 140
2026
Q1 		$612K Buy
+37,229
New +$712K 0.09% 174

Other funds holding GLUE

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aisling Capital Management
Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Round Rock Advisors's GLUE Position: Q3 2026 in Review

Round Rock Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 37,229 shares — an estimated $901K sold.

Round Rock Advisors first reported a position in GLUE in Q1 2026 and held it in 2 quarters. The position peaked at $901K in Q2 2026. 91 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Round Rock Advisors reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Round Rock Advisors sold 37,229 Monte Rosa Therapeutics shares in Q3 2026, an estimated $901K.
  • Round Rock Advisors first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 2 quarters.
  • Round Rock Advisors's Monte Rosa Therapeutics position peaked at $901K in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Round Rock Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.